MTN 003B

January 26, 2015

Bone Mineral Density Substudy to MTN 003 (VOICE)

Sponsors:
US National Institute of Allergy and Infectious Diseases (NIAID)
Division of AIDS (DAIDS)
US National Institutes of Health (NIH)

Protocol Summary:
MTN 003B is a substudy of MTN 003 (VOICE), which will compare changes in bone mineral density (BMD) after one year among VOICE participants receiving oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)/TDF compared with oral placebo.

Years: 2009 – 2014

Investigators:
Z.M. Chirenje, MD, FRCOG
Tsitsi Magure, MBChB, MMed

Locations: Spilhaus, Seke South, and Zengeza CRSs

MTN

Completed Study

Publication:

Mgodi NM, Kelly C, Gati B, et al. Factors Associated with Bone Mineral Density in Health African Women. Arch Osteoporos. 2015;10:206.

Mirembe BG, Kelly CW, Mgodi N, et al. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94.